Cheng et al., 2019 - Google Patents
Prospective comparison of (4 S)-4-(3-18 F-fluoropropyl)-l-glutamate versus 18 F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal …Cheng et al., 2019
View PDF- Document ID
- 15138928316486544678
- Author
- Cheng M
- Huang Y
- Ho B
- Kuo T
- Hsin L
- Shiue C
- Kuo H
- Jeng Y
- Yen R
- Tien Y
- Publication year
- Publication venue
- European Journal of Nuclear Medicine and Molecular Imaging
External Links
Snippet
Abstract Purpose (4 S)-4-(3-18 F-Fluoropropyl)-l-glutamate (FSPG) positron emission tomography (PET) reflects system x C− transporter (xCT) expression. FSPG PET has been used to detect brain, lung, breast and liver cancer with only modest success. There is no …
- 201000008129 pancreatic ductal adenocarcinoma 0 title abstract description 103
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Evans et al. | Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease | |
Maurer et al. | Current use of PSMA–PET in prostate cancer management | |
Baek et al. | Exploratory clinical trial of (4 S)-4-(3-[18F] fluoropropyl)-l-glutamate for imaging xC− transporter using positron emission tomography in patients with non–small cell lung or breast cancer | |
Kunikowska et al. | 68Ga–Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme? | |
Cheng et al. | Prospective comparison of (4 S)-4-(3-18 F-fluoropropyl)-l-glutamate versus 18 F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study | |
Kavanaugh et al. | Utility of [18 F] FSPG PET to image hepatocellular carcinoma: first clinical evaluation in a US population | |
Baek et al. | (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies | |
Xie et al. | Prognostic value of 18 F-FDG PET-CT metabolic index for nasopharyngeal carcinoma | |
Henry et al. | Human epidermal growth factor receptor 2-targeted PET/single-photon emission computed tomography imaging of breast cancer: noninvasive measurement of a biomarker integral to tumor treatment and prognosis | |
Specht et al. | Advances in molecular imaging for breast cancer detection and characterization | |
Oh et al. | Prostate-specific membrane antigen PET imaging in prostate cancer: opportunities and challenges | |
Kunikowska et al. | [68 Ga] Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma | |
Artigas et al. | 68 Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy | |
Tripathi et al. | VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man | |
Mix et al. | Performance of 111 In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy | |
Lee et al. | Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation | |
Wang et al. | A prospective head-to-head comparison of [68Ga] Ga-P16-093 and [68Ga] Ga-PSMA-11 PET/CT in patients with primary prostate cancer | |
Vallejo-Armenta et al. | 99mTc‐CXCR4‐L for imaging of the chemokine‐4 receptor associated with brain tumor invasiveness: biokinetics, radiation dosimetry, and proof of concept in humans | |
Krarup et al. | New PET tracers: current knowledge and perspectives in lung cancer | |
Zhu et al. | Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma | |
Vallejo-Armenta et al. | [99mTc] Tc-iPSMA SPECT brain imaging as a potential specific diagnosis of metastatic brain tumors and high-grade gliomas | |
He et al. | Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms | |
Cai et al. | Non-invasive monitoring of HER2 expression in breast cancer patients with 99mTc-Affibody SPECT/CT | |
Mertan et al. | PET imaging of recurrent and metastatic prostate cancer with novel tracers | |
Ahrens et al. | Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion |